Arrhythmia

Data from the SMART WARS study provides insight into the diagnostic utility of the KardiaBand and Apple Watch Series 4 devices for detecting arrhythmias in older adults.

Results of DECAAF II, an RCT assessing MRI-guided ablation plus PVI to PVI alone for persistent AFib, suggest the more aggressive approach did not result in a statistically significant difference in arrhythmia recurrence but was associated with increased occurrence of safety events, including stroke.

A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.

Solomon Sager, MD, shares his experience using ICMs in clinical practice for patients with atrial fibrillation and syncope.

An expert in cardiovascular medicine provides insight on long-term monitoring solutions in the pipeline for the management of atrial fibrillation and syncope.

Dr. Solomon Sager assesses the benefit of earlier ICM use on patients and providers for the management of atrial fibrillation and syncope.

An expert in cardiovascular medicine comments on how the technology of ICMs has evolved and evaluates the use of ICMs for patients fibrillation who are at high risk for syncope.

Solomon Sager, MD, reviews the benefits of cardiac monitoring with insertable devices and how it can guide treatment decision-making in patients with atrial fibrillation.

A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.

Dr Deepak L. Bhatt shares considerations for managing patients with atrial fibrillation, including rate control vs rhythm control and the use of anticoagulation methods.

An expert in cardiovascular medicine examines current challenges associated with the treatment of atrial fibrillation.

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, discusses the clinical presentation of atrial fibrillation in patients and assesses the relationship between atrial fibrillation and syncope.

Dr Deepak L. Bhatt provides insight on approaching the diagnosis of atrial fibrillation and the burden on patients, providers, and the overall health care system.

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, reviews the prevalence of atrial fibrillation and risk factors for developing the disease.

A study from HRS 2022 suggests Black patients with AFib were 25% less likely to be on oral anticoagulants at hospital discharge compared to their White counterparts those discharged 18% less likely to receive DOACs than their White counterparts.

Data from the VITAL-AF trial indicate universal screening with single-lead ECGs among patients 65 years and older in primary care settings did not significantly increase in new atrial fibrillation diagnoses, but was more effective in patients aged 85 years or older.

An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.

Implicity announced their ILR ECG Analyzer received 510(k) clearance from the FDA in a statement released on December 16.

A retrospective analysis of data from a Chicago School of Medicine care center provides insight into the apparent increase in risk of atrial fibrillation among patients with sickle cell disease.

A recent analysis found patients with diabetes were about 26% less likely to notice symptoms of atrial fibrillation and more likely to experience more comorbidities than their counterparts without diabetes.

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.

Data from the Fitbit Heart study presented at AHA 2021 suggest a novel algorithm for detecting irregular heart rhythms had a positive predictive value of 98% for detecting atrial fibrillation in patients with undiagnosed atrial fibrillation.

After 2 years, there was little difference in cognitive function between patients with nonvalvular atrial fibrillation receiving dabigatran or warfarin in the GIRAF trial, which was presented at AHA 2021.

A meta-analysis and systematic review of 7 RCTs suggests consuming more than 1 gram of marine omega-3 fatty acid supplements per day could increase a patient's risk of atrial fibrillation.

Data from more than 800 patients with 120 days of continuous heart monitoring data and ischemic stroke provide insight into the timing of arrhythmic episodes and how it can help predict the risk of stroke in patients with CIEDs and atrial fibrillation.